What is the COPPAR Study?
The Brigham and Women’s Hospital Cohort for Psoriasis and Psoriatic Arthritis Registry (COPPAR) is a study focused on understanding the natural course of psoriatic disease.
We aim to improve the quality of life of patients living with psoriasis (PsO)/psoriatic arthritis (PsA) and provide the best treatment for specific patient characteristics.
Goals of COPPAR
The goal of the COPPAR study is to establish a prospective observational cohort of Psoriatic Arthritis patients to:
- Evaluate the natural history of the disease
- Determine biological, clinical, and environmental predictors of PsA among patients initially presenting with PsO
- Identify predictors of treatment response and failure and characterize treatment transitions.
- Quantify health services utilization and quality of life of patients with PsO and PsA
- Assess relevant subgroups of patients with specific phenotypes, including non-plaque disease (e.g., nail disease, palmar-plantar, genital, inverse)
- Determine the effectiveness and safety of new treatments
Why is COPPAR important?
Disease registries can fill an important gap for improving the understanding of chronic diseases with various treatment strategies. They capture patients in routine care “real-world” settings and collect information on clinical details, biologic materials, patient-reported outcomes, and clinical treatment pathways. For patients with psoriasis (PsO) and psoriatic arthritis (PsA), there are few disease registries in the Americas. Despite the existing registries, a recent review paper concludes with a call for more PsA registries with systematic capture of patient-reported outcomes and bio-specimens. Furthermore, the development of systemic arthritis in patients with PsO remains a challenging research topic; thus, a combined PsO and PsA registry provides essential research opportunities.